AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ACRV

Blume-Jensen Peter sold $973 of ACRV (indirect holdings)

Blume-Jensen Peter (President and CEO) sold 484 indirectly-held shares of Acrivon Therapeutics, Inc. (ACRV) at $2.01 on 2026-08-18. Filed jointly with Masson Kristina (EVP - Business Operations).

Original reporting
SEC EDGAR · Blume-Jensen Peter, Masson Kristina
Published Aug 20, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACRV
Neutral
high confidence
Mentioned
$ACRV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACRVNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock.

02

Market read

Limited relevance; typical insider transaction with minimal market effect.

03

What to watch

No 10b5‑1 plan; sale appears discretionary.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-20

Background

SEC Form 4 filing reports insider transaction for Acrivon Therapeutics.

Company-level read

Ticker impact

$ACRVNeutralHigh confidence
Context

Form 4 disclosed President and CEO Peter Blume-Jensen sold 484 shares for $972.84 on 2026-08-18.

Expected impact

little to no immediate effect

Evidence & confidence

Sale size is small relative to holdings and market cap; no pre‑arranged plan.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market only minimally affected.

Global

None

Counterpoint

What could challenge this read

Insider sell could signal concerns, but size is trivial.

Key entities

  • Executive
    Peter Blume-Jensen

    President and CEO of Acrivon Therapeutics

  • Company
    Acrivon Therapeutics, Inc.

    Biotech firm listed on Nasdaq under ACRV

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACRV insider trading history →

Related articles

$ACRVMedAI 8/10

Acrivon Therapeutics Highlights Phase 2-Ready ACR-525 and Preclinical EoE Programs

Acrivon Therapeutics presented its immunology and inflammation programs, including the Phase 2-ready ACR-525, a selective JAK1 inhibitor, and a preclinical PKCθ inhibitor program, at an R&D event. The company highlighted EoE's growing patient population and treatment gaps as rationale for ACR-525's development, citing favorable early clinical data and safety profile. The presentation is available on the company's investor website.

tradingview.com
$ACRVMedAI 8/10

Acrivon to present cancer drug trial data at November symposium

Acrivon Therapeutics (ACRV) will present Phase 1/2 trial data for ACR-2316 at a cancer symposium in November. The study showed clinical activity in endometrial and lung cancers, with one patient achieving complete response. The trial has progressed to dose expansion, including pancreatic cancer patients. ACRV uses its AP3 platform to predict patient responses.

investing.com
$ACRVMedAI 8/10

Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing

Acrivon Therapeutics (ACRV) announced the advancement of ACR-7280, an oral CDK11 inhibitor, as its next development candidate. The company plans to file an IND application for the drug with the FDA in the first half of 2027. ACR-7280 showed complete tumor regression in AML xenograft models and potential in combination therapies. Acrivon's lead program, ACR-368, is in a Phase 2 trial for endometrial cancer.

investing.com
$ACRVMed

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 P

SEC EDGAR 8-K